STAT

NOVEMBER 12, 2024

Pfizer’s promising research on a treatment for a dangerous cancer-related condition is also helping prove out the value of wearables in clinical trials. In September, the pharma giant reported results showing that an experimental antibody could positively impact people with cachexia, a complication sometimes called “wasting syndrome” that can cause people with cancer to lose weight and make it harder for them to tolerate treatments.

138

138

Pharmacy Times

NOVEMBER 12, 2024

Failing is not final, and it does not define what kind of pharmacist or resident a student can be.

145

145

STAT

NOVEMBER 12, 2024

The company behind ChatGPT didn’t set out to tackle health care.

Hospitals 133

Hospitals 133

Pharmacy Times

NOVEMBER 12, 2024

There were differences in the variables that influenced vaccination decision making for adults aged 18 to 26 years and for parents making the decision to vaccinate their child

Vaccines 139

Vaccines 139

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

STAT

NOVEMBER 12, 2024

The last time Mark Palinski went to a Narcotics Anonymous meeting, he was asked to leave and never come back. He stills remembers the argument: All he had done was advocate for the use of the “gold standard” treatment opioid addiction, a common medication called buprenorphine.  To Palinski, buprenorphine is a godsend.

145

145

Pharmacy Times

NOVEMBER 12, 2024

Kristi Veis discusses the importance of flu vaccinations and the role of pharmacists in administering them.

Vaccines 132

Vaccines 132

Pharmacy Times

NOVEMBER 12, 2024

High COVID-19 hospital caseload strain led to increases in inpatient adverse events among patients both with and without SARS-CoV-2 infection.

Hospitals 132

Hospitals 132

STAT

NOVEMBER 12, 2024

Biotech startup Orna Therapeutics has cut more jobs in its second round of layoffs in the last year, STAT has learned.  Orna was part of a buzzy cohort of companies established in the wake of the Covid pandemic, planning to create a new, more durable type of RNA-based medicines. It launched in 2021 and quickly garnered attention from Gilead subsidiary Kite Pharma, Bristol Myers Squibb, Novartis, and Merck.

124

124

Pharmacy Times

NOVEMBER 12, 2024

According to the study, 20% of patients with myeloproliferative neoplasms progress to blast phase.

132

132

STAT

NOVEMBER 12, 2024

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of lung cancer, a step that will delay the drug’s arrival on the market and that will add to questions about how widely it could be used.  The medicine, datopotamab deruxtecan, or Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies have been pouring investments into.

Chemotherapy 117

Chemotherapy 117

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

NOVEMBER 12, 2024

Africa’s rapidly growing population, expected to reach 2.5 billion by 2050, means an increasing demand for health care and medications.

123

123

Fierce Pharma

NOVEMBER 12, 2024

Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns” in the road ahead, Bayer is confident that the course it’s laid out th | As Xarelto generics continue to eat away at sales, Bayer's Nubeqa and Kerendia are picking up the slack while Regeneron-partnered Eylea makes for a solid base.

115

115

Pharmacy Times

NOVEMBER 12, 2024

Ocrelizumab (Ocrevus; Genentech) is used for the management and treatment of multiple sclerosis.

123

123

Fierce Pharma

NOVEMBER 12, 2024

After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to slim down by divesting its hospital drugs unit,

Hospitals 114

Hospitals 114

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

NOVEMBER 12, 2024

LBL-034 could be best in class in treating individuals with multiple myeloma.

FDA 123

FDA 123

Drug Topics

NOVEMBER 12, 2024

Pharmacy law experts detailed the Drug Supply Chain Security Act, highlighting the role each entity within the supply chain plays in ensuring the safety and authenticity of US prescription drugs.

112

112

Fierce Healthcare

NOVEMBER 12, 2024

The Department of Justice filed suit on Tuesday to block UnitedHealth's $3.3 billion acquisition of home health company Amedisys, arguing that the deal would stifle competition in this space. | The Department of Justice filed suit on Tuesday to block UnitedHealth's $3.3 billion acquisition of home health company Amedisys, arguing that the deal would stifle competition in this space.

109

109

pharmaphorum

NOVEMBER 12, 2024

Daiichi Sankyo and AstraZeneca give up on their NSCLC application for Dato-DXd, and refile seeking a narrower label

Labelling 105

Labelling FDA 105

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

NOVEMBER 12, 2024

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused trials.

Vaccines 104

Vaccines FDA 104

pharmaphorum

NOVEMBER 12, 2024

'Game-changer' daily pill to quit smoking returns to NHS after three-year absence after a deal between Teva and NHS England

103

103

Drug Topics

NOVEMBER 12, 2024

A recent study found that with greater depression severity, metabolic and clinical characteristics such as HbA1c, fasting blood glucose, and triglyceride levels increased.

98

98

pharmaphorum

NOVEMBER 12, 2024

Neurogene says Rett syndrome gene therapy improves clinical symptoms, but a serious adverse event causes shares to fall

98

98

Drug Topics

NOVEMBER 12, 2024

High copayments can be a structural barrier to medication therapy adherence.

98

98

pharmaphorum

NOVEMBER 12, 2024

The United Nations is calling for urgent global action to address the growing threat of antimicrobial resistance (AMR). Learn more about this pressing issue and what steps can be taken to combat it effectively.

98

98

Drug Topics

NOVEMBER 12, 2024

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

FDA 98

FDA 98

The Checkup by Singlecare

NOVEMBER 12, 2024

First came Ozempic , then “Oatzempic,” the viral social media trend that has people drinking their oats in the name of weight loss. It’s no surprise that given constipation and other side effects sometimes associated with GLP-1 drugs like Wegovy and Mounjaro , people have turned to alternative options. But does blending your oats actually work? Despite its catchy name and online buzz, “the ‘Oatzempic’ drink is not a medication or an equivalent substitute for Ozempic or other GLP-1 agonists, and

Insurance 94

Insurance 94

Drug Topics

NOVEMBER 12, 2024

Cassandra Esperant, PharmD, AAHIVP, leverages her expertise as a clinical pharmacist to advocate for the well-being of individuals with HIV.

98

98

STAT

NOVEMBER 12, 2024

Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascots are bounding about the grounds in search of creatures to annoy. As for us, we are as busy as ever hunting and gathering items of interest. We trust you have your own hectic agendas. So join us as we hoist the ever-present cup of stimulation — our choice today is coconut rum — and attack the fast-growing to-do list.

Chemotherapy 93

Chemotherapy Insurance 93

Drug Topics

NOVEMBER 12, 2024

FDA experts gathered to discuss the DEA’s rescheduling of marijuana and how it will impact the pharmaceutical supply chain.

FDA 98

FDA 98

Outsourcing Pharma

NOVEMBER 12, 2024

Abbiskoâs small molecule drug pimicotinib has smashed the primary goal of a phase 3 trial for the treatment of tenosynovial giant cell tumor (TGCT), taking the asset a step further to the market in China and elsewhere.

92

92

pharmaphorum

NOVEMBER 12, 2024

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.The German group said the CSF-1R inhibitor given as a once-daily, oral dose hit its primary endpoint in the MANEUVER study, achieving an objective response rate (ORR) at week 25 of 54% compared to 3.2% for a matched placebo in patients with TGCT, a rare disease affecting the joints and tendons.

103

103

Outsourcing Pharma

NOVEMBER 12, 2024

Abbisko’s small molecule drug pimicotinib has smashed the primary goal of a phase 3 trial for the treatment of tenosynovial giant cell tumor (TGCT), taking the asset a step further to the market in China and elsewhere.

81

81

Fierce Pharma

NOVEMBER 12, 2024

Citing a rosy view of the U.S. | AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total capital investment of $3.5 billion. The cash will be used to grow the company’s research and production footprint in the States by the end of 2026, generating more than 1,000 new jobs along the way.

75

75